Varicella zoster virus infection due to Pfizer-BioNTech mRNA COVID-19 vaccine and sinovac vaccine in two relapsing-remitting multiple sclerosis patients during fingolimod therapy

Along with the Covid-19 infection, newly developed Covid-19 vaccines have also entered our lives. While the immunomodulatory/immune suppressor treatments are used mainly in individuals with diseases affecting the immune system like multiple sclerosis, possible side effects that may develop due to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Faruk, Turan Ömer, Koseoglu, Mesrure, Rabia, Koc Emine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier B.V. 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848722/
http://dx.doi.org/10.1016/j.nerep.2022.100078
_version_ 1784652315305705472
author Faruk, Turan Ömer
Koseoglu, Mesrure
Rabia, Koc Emine
author_facet Faruk, Turan Ömer
Koseoglu, Mesrure
Rabia, Koc Emine
author_sort Faruk, Turan Ömer
collection PubMed
description Along with the Covid-19 infection, newly developed Covid-19 vaccines have also entered our lives. While the immunomodulatory/immune suppressor treatments are used mainly in individuals with diseases affecting the immune system like multiple sclerosis, possible side effects that may develop due to the vaccines applied have begun to be followed closely. Varicella-zoster virüs (VZV) reactivation also seems to be one of the complications after various Covid-19 vaccines. Here, we presented two patients who developed HZ infection after being vaccinated with two different vaccines (Pfizer-BioNTech mRNA COVID-19 and Sinovac) and thought to be related to the possible vaccine.
format Online
Article
Text
id pubmed-8848722
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-88487222022-02-18 Varicella zoster virus infection due to Pfizer-BioNTech mRNA COVID-19 vaccine and sinovac vaccine in two relapsing-remitting multiple sclerosis patients during fingolimod therapy Faruk, Turan Ömer Koseoglu, Mesrure Rabia, Koc Emine Neuroimmunology Reports Case Series Along with the Covid-19 infection, newly developed Covid-19 vaccines have also entered our lives. While the immunomodulatory/immune suppressor treatments are used mainly in individuals with diseases affecting the immune system like multiple sclerosis, possible side effects that may develop due to the vaccines applied have begun to be followed closely. Varicella-zoster virüs (VZV) reactivation also seems to be one of the complications after various Covid-19 vaccines. Here, we presented two patients who developed HZ infection after being vaccinated with two different vaccines (Pfizer-BioNTech mRNA COVID-19 and Sinovac) and thought to be related to the possible vaccine. The Author(s). Published by Elsevier B.V. 2022 2022-02-16 /pmc/articles/PMC8848722/ http://dx.doi.org/10.1016/j.nerep.2022.100078 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Case Series
Faruk, Turan Ömer
Koseoglu, Mesrure
Rabia, Koc Emine
Varicella zoster virus infection due to Pfizer-BioNTech mRNA COVID-19 vaccine and sinovac vaccine in two relapsing-remitting multiple sclerosis patients during fingolimod therapy
title Varicella zoster virus infection due to Pfizer-BioNTech mRNA COVID-19 vaccine and sinovac vaccine in two relapsing-remitting multiple sclerosis patients during fingolimod therapy
title_full Varicella zoster virus infection due to Pfizer-BioNTech mRNA COVID-19 vaccine and sinovac vaccine in two relapsing-remitting multiple sclerosis patients during fingolimod therapy
title_fullStr Varicella zoster virus infection due to Pfizer-BioNTech mRNA COVID-19 vaccine and sinovac vaccine in two relapsing-remitting multiple sclerosis patients during fingolimod therapy
title_full_unstemmed Varicella zoster virus infection due to Pfizer-BioNTech mRNA COVID-19 vaccine and sinovac vaccine in two relapsing-remitting multiple sclerosis patients during fingolimod therapy
title_short Varicella zoster virus infection due to Pfizer-BioNTech mRNA COVID-19 vaccine and sinovac vaccine in two relapsing-remitting multiple sclerosis patients during fingolimod therapy
title_sort varicella zoster virus infection due to pfizer-biontech mrna covid-19 vaccine and sinovac vaccine in two relapsing-remitting multiple sclerosis patients during fingolimod therapy
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848722/
http://dx.doi.org/10.1016/j.nerep.2022.100078
work_keys_str_mv AT farukturanomer varicellazostervirusinfectionduetopfizerbiontechmrnacovid19vaccineandsinovacvaccineintworelapsingremittingmultiplesclerosispatientsduringfingolimodtherapy
AT koseoglumesrure varicellazostervirusinfectionduetopfizerbiontechmrnacovid19vaccineandsinovacvaccineintworelapsingremittingmultiplesclerosispatientsduringfingolimodtherapy
AT rabiakocemine varicellazostervirusinfectionduetopfizerbiontechmrnacovid19vaccineandsinovacvaccineintworelapsingremittingmultiplesclerosispatientsduringfingolimodtherapy

Ejemplares similares